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ABSTRACT.
Purpose: The advances in medicine have led to an increased number of people
living with some form of immunodeﬁciency. Most ocular infections in immuno-
compromised patients may lead to irreversible blindness. We identify the causes
of uveitis in immunocompetent and immunocompromised patients.
Methods: A retrospective cohort study of 1354 consecutive patients. All patients
underwent a standard work-up for uveitis.
Results: An immunocompromised state was identiﬁed in 171/1354 patients
(13%), of whom 40 had Human immunodeﬁciency virus (HIV) infection, 52
received immunosuppressive medications, 28 had concurrent malignant disorder
and 20 had other causes for their immunosuppression. In addition, 93/1354
patients (7%) had diabetes mellitus (DM). The prevalence of intraocular
infections was much higher in immunocompromised patients than in immuno-
competent patients and DM (p < 0.001). Causes of uveitis diﬀered between the
diverse immunocompromised groups. The non-HIV immunocompromised
patients showed primarily intraocular herpes simplex and varicella zoster virus
infections, whilst HIV-positive patients exhibited frequently cytomegalovirus
(CMV) retinitis and syphilis. Patients with generalized malignancies were
characterized by a lower prevalence of infections and higher prevalence of
sarcoidosis. Patients with DM typically showed sarcoidosis and bacterial
intraocular infections. The percentage of undetermined uveitis diagnoses was
markedly lower in immunosuppressed patients (p < 0.001).
Conclusion: In immunocompromised patients with uveitis, infections were
diagnosed in 46% of cases in contrast to 12% in the immunocompetent patients.
The causes of uveitis diﬀered among the various types of immunosuppression.
Immunocompromised patients with uveitis require a rapid assessment for the
most expected infections.
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Introduction
Uveitis is a clinical syndrome of mul-
tiple origins, which can lead to perma-
nent visual impairment and blindness.
Uveitis can be principally divided into
infectious or non-infectious category
and the early distinction is essential for
the treatment and visual outcome of
the patients.
The advances in therapy for
malignancies and autoimmune disor-
ders together with the improved options
in transplantation medicine have led to
an increased number of people living
with some form of immunodeﬁciency.
Obviously, the speciﬁc causes and clin-
ical impact of uveitis diﬀer between
immunocompromised and immuno-
competent patients. In immunocompe-
tent patients, the most frequently
encountered uveitis types are associated
with systemic non-infectious immune
mediated diseases (Barisani-Asenbauer
et al. 2012; Bajwa et al. 2015; Jones
2015; Llorenc et al. 2015; Luca et al.
2017; Zagora et al. 2017). In contrast,
the causes of uveitis in immunocompro-
mised patients include predominantly
opportunistic infections (Westeneng
et al. 2007). Recognition of the exact
cause of uveitis in immunocompro-
mised patients is challenging, as clinical
features are commonly overlapping,
infections might have multiple origins
and moreover, results of laboratory
tests are often not reliable. Moreover,
since serologic tests are not informative
on local processes occurring in the eye,
the conﬁrmation of infection from
intraocular ﬂuid samples is imperative.
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Herein, we assess the immune status
of 1354 consecutive patients with uvei-
tis and relate the causes of intraocular
inﬂammation to the immune status of
the patients.
Patients and Methods
Study population
We conducted a retrospective cohort
study at the department of Ophthalmol-
ogy of the Erasmus Medical Center
(Rotterdam, The Netherlands), which
represents a tertiary referral centre. This
study was performed with the approval
of the Medical Ethics Committee of our
institution. All data were extracted from
medical records of patients and the
research has followed the Tenets of the
Declaration of Helsinki.
Between September 2012 andDecem-
ber 2016, 1454 consecutive patients with
uveitis were seen in our institution.
Excluded were 23 patients, of whom
clinical data from the time of onset of
uveitis were lacking. An additional 77
patients with masquerade syndromes
were excluded, including 22 with malig-
nant disease (16 with large B-cell lym-
phomas, 2 with iris metastases of a
carcinoma, 1 with retinoblastoma, 1
with a melanoma, 1 with a medulloep-
ithelioma and 1 patient with chronic
lymphatic leukaemia) and 55 with
benign masquerade syndromes (19 with
hereditary ocular disorder, 17 with vas-
cular, 6 with degenerative and 3 with
neurological diseases, 3 with retinal
detachments, 4 with chronic serous
chorioretinopathy, and 2 with compli-
cations following intraocular surgery).
Finally, we included 1354 patients with
uveitis in the present study.
All patients underwent a standard
work-up for uveitis, which included
erythrocyte sedimentation rate, blood
counts, serum angiotensin-converting
enzyme levels, serology for syphilis as
well as interferon gamma release assay
test (QuantiFERON–TB Gold In-Tube
test). Radiologic chest imaging was also
performed. Human Leukocyte Antigen
B27 testing was performed in patients
with anterior and panuveitis. According
to the clinical manifestations, additional
examinationsand referral to appropriate
subspecialists were performed (tailored
approach). The addition of the
QuantiFERON–TB Gold In-Tube test
to the screening was performed in 2013.
Human immunodeﬁciency virus (HIV)
test was not included in a routine work-
up for uveitis and was included in all
patients with positive syphilis serology
and in patients in whom HIV infection
was suspected because of clinical presen-
tation and/ormedical history. Deﬁnitive
anatomical classiﬁcation was performed
(e.g. localizationand laterality of uveitis)
according to the Standardization of
Uveitis Nomenclature (SUN) Working
Group (Jabs et al. 2005).
Diagnoses were grouped into infec-
tious and non-infectious diseases and in
established clinical ocular syndromes
(e.g. birdshot chorioretinopathy).
Patients with established ocular syn-
dromes and identiﬁed cause or associa-
tion with systemic disorder (e.g. Fuchs
uveitis syndrome with documented
rubella virus infection or pars planitis
with multiple sclerosis) were classiﬁed
according to the cause of their uveitis
and not according to their ocular syn-
drome (Jabs et al. 2005). Patients with a
positive Interferon Gamma Release
Assay test in the presence of unex-
plained uveitis were classiﬁed as of
unknown origin. All intraocular infec-
tions were proven by intraocular ﬂuid
analysis with some exceptions: ocular
syphilis was diagnosed in patients with
positive serologic reactions indicating
active syphilis. Ocular tuberculosis was
diagnosed only in patients with uveitis
and active systemic tuberculosis infec-
tion proven either by culture or PCR
from aﬀected organs. The diagnosis of
deﬁnitive sarcoidosis was based on his-
tological conﬁrmation and the diagnosis
of presumed sarcoidosis on radiologic
abnormalities consistent with the
diagnosis of sarcoidosis (mostly sym-
metrical hilar lymphadenopathy) (Her-
bort et al. 2009). Patients with
laboratory features suggesting sarcoido-
sis but without tissue biopsy or typical
radiologic features were diagnosed as of
unknown origin (Acharya et al. 2018).
Histological features of sarcoid reac-
tions in malignancy cannot be histolog-
ically diﬀerentiated from genuine
sarcoidosis as the main diﬀerence lies
in location of the lesions and concurrent
malignancy (Tchernev et al. 2014).
Since patients with ocular sarcoidosis
might have extrapulmonary involve-
ment only, all patients with positive
tissue biopsies were classiﬁed as sar-
coidosis and subsequently, patients with
malignancy and sarcoid reactions are
indicated separately. Human leukocyte
antigen (HLA) B27-associated uveitis
was classiﬁed as a systemic immune
mediated disorder (whether or not with
proven ankylosing spondylitis). Our
policy is to refer to rheumatologist (or
other specialist) solely HLA B27-posi-
tive patients with rheumatologic com-
plaints. In consequence, not all patients
underwent rheumatologic evaluation
and the exact prevalence of HLA B27-
associated systemic disease is not
known. As we believe that HLA B27-
associated uveitis is the same entity
whether or not associated with ankylos-
ing spondylitis, we decided to categorize
the patients in the same group. All other
speciﬁc diagnoses were performed
according to current diagnostic criteria.
None of our patients used immune
checkpoint inhibitors or other
immunostimulatory drugs.
Table 1. Criteria for Immune Deﬁciency or Suppression (adapted from Bonten et al. 2015).
Presence of 1 or more of the following conditions:
Congenital immunodeﬁciency syndromes
Human immunodeﬁciency virus (HIV) infection and CD4+ cells <300/mm³
Sepsis and short recovery period immediately after major surgery
Leukemia (presence deﬁned as having been treated by or been eligible for treatment by
radiotherapy and/or chemotherapy within the last 5 years)
Lymphoma (presence deﬁned as having been treated by or been eligible for treatment by
radiotherapy and/or chemotherapy within the last 5 years)
Hodgkin disease (presence deﬁned as having been treated by or been eligible for treatment by
radiotherapy and/or chemotherapy within the last 5 years)
Multiple myeloma (presence deﬁned as having been treated by or been eligible for treatment by
radiotherapy and/or chemotherapy within the last 5 years)
Generalized malignancy (deﬁned as presence of any malignancy that had been treated by or had
been eligible for treatment by radiotherapy and/or chemotherapy within the last 5 years)
Receipt of an organ or bone marrow transplant
Concurrent use of immunosuppressive therapy, including steroids in the daily dose above 7.5 mg
for at least 4 weeks. (Inhaled, intraarticular and topical steroids were not considered
immunosuppressive.)
Chronic renal failure (deﬁned as receipt of renal dialysis or transplant) or nephrotic syndrome
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Criteria for an immunocompro-
mised state were based on the earlier
deﬁnition of Bonten et al. (2015)
with some modiﬁcations (Table 1).
Immunosuppressed patients were fur-
ther subdivided according to their HIV
status, the reasons for immunosuppres-
sive therapy (transplantations, malig-
nancy and non-malignant disease), and
other causes of their immune impair-
ment.
Diabetes mellitus (DM) is associated
with impaired innate and adapted
immune responses and is characterized
by an increased risk of infections and
their complications (Berrou et al. 2013;
Hodgson et al. 2015; Jafar et al. 2016).
Hyperglycaemia, impaired neutrophil
migration and phagocytosis as well as
the state of chronic inﬂammation in
DM are herein involved. Immune
responses during pregnancy are shifted
towards an anti-inﬂammatory status,
which is advantageous for the outcome
of pregnancy but might inﬂuence the
course of immune-mediated disorders
and infections (Robinson & Klein
2012; Graham et al. 2017). Though
not immunosuppressed, pregnant
females might show a diﬀerent spec-
trum of uveitis and therefore are spec-
iﬁed separately as well as patients with
DM and HIV infections and CD4+
T cell counts above 300 cells/mm3.
The following characteristics were
extracted: gender, race, age at onset
of uveitis, established causes of uveitis
and/or associated systemic diseases.
Results
The anatomical classiﬁcation of uveitis
is depicted in Table 2. Immune status
of the patients and classiﬁcation of
uveitis are presented in Table 3.
Immune deﬁciency or suppression was
identiﬁed in 171/1354, 13% of all
patients. The prevalence of posterior
uveitis was higher in immunocompro-
mised patients (79/171 versus 258/1075;
p < 0.001).
The prevalence of infections was
much higher in immunocompromised
patients compared to immunocompe-
tent patients (78/171, 46% versus 125/
1075,12%; p < 0.001). The most preva-
lent infections in immunocompromised
patients were viral infections, particu-
larly cytomegalovirus (CMV), followed
by herpes simplex virus (HSV) and
varicella zoster virus (VZV). Viruses
represented most common infections
also in immunocompetent patients, but
included predominantly infections with
rubella virus and HSV/VZV. All
immunocompetent patients with CMV
(n = 3) had anterior uveitis. The per-
centage of undetermined uveitis diag-
noses was similar in immunocompetent
patients and patients with DM, but was
lower in immunosuppressed patients
(35/171 versus 420/1075, p < 0.001).
Diabetes mellitus (DM) at onset of
uveitis was present in 93/1354, 7%
patients. Patients with DM had a low
prevalenceof infectiousuveitis, similar to
immunocompetent patients (8/93, 9%
versus 125/1075, 12%; p = 0.378).
PatientswithDMtypically suﬀered from
bacterial intraocular infections (mostly
endogenous endophthalmitis, Table 3).
The number of pregnant patients
and HIV-positive patients with CD4
cells above 300/mm³ was limited and
did not allow meaningful comparisons.
Majority of HIV-positive patients with
CD4+ T cells above 300/mm³ had
infectious uveitis, mostly syphilis.
Various types of immune impairment
and causes of uveitis are depicted in
Table 4. Out of 171 immunocompro-
mised patients, 40 had HIV infection
with CD4 positive cells <300 cells/mm3
and 52 received immunosuppressive
medications (17 for organ and/or stem
cell transplants, 18 for malignant disor-
ders and 17 for not malignant diseases).
No diﬀerences in uveitis causes or asso-
ciations were noted when patients with
the various causes for immunosuppres-
sive therapy were compared. In the 17
patients who developed uveitis after
stem cell/organ transplant, the interval
time between transplant and onset of
uveitis was 36 months. Only one trans-
plant patient developed uveitis during
his prophylactic regimen with antibiotic
and antiviral drugs. Three transplant
patients had concurrent systemic infec-
tion (2 had candidemia related to their
ocular disorder and one had human
metapneumovirus infection) and one
additional patient had localized VZV
in the V1 dermatome. Of the 15 patients
with haematological malignancy, 10
had intraocular infections (5 HSV/
VZV, 4 CMV, 1 candida). Further, 28
patients had generalized malignancy
(but no current immunosuppressive
treatment) and 22 had other various
causes for their immunosuppression,
such as congenital immunodeﬁciency,
sepsis and others.Additional 31 patients
received immunosuppressive medica-
tions for their systemic disease, which
also caused their uveitis (e.g. sarcoido-
sis, Behcet’s disease, inﬂammatory
bowel disease). These patients devel-
oped uveitis while on immunosuppres-
sive treatment for systemic disorder and
their uveitis improved with the increase
of immunosuppressive medication. The
development of uveitis in these patients
was therefore not related to their
immunosuppression.
The spectrum of infections in various
immunocompromised groups
HIV-positive patients exhibited most
frequently CMV retinitis, followed by
syphilitic uveitis whilst the non-HIV
immunosuppressed patients had most
commonly intraocular HSV/VZV
infections. Cytomegalovirus (CMV)
infections (all retinitis) developed also
in non-HIV patients, speciﬁcally in
patients with hematologic malignancies
(n = 4), receiving immunosuppressive
therapy for not malignant disease
Table 2. Anatomical classiﬁcation of uveitis according to immune status of the patients*.
No evidence of
immune suppression
(N = 1075)
Diabetes
mellitus†
(N = 93)
Immune deﬁciency or
suppression, total‡
(N = 171)
N (%) N (%) N (%)
Anterior 386 (36) 36 (39) 55 (32)
Intermediate 107 (10) 5 (5) 6 (3)
Posterior 258 (24) 18 (19) 73 (43)
Panuveitis 291 (27) 27 (29) 32 (19)
Scleritis/sclerouveitis 33 (3) 7 (7) 5 (3)
* Not included are 8 patients with HIV infection with CD4+ Tcells >300 cells/mm3 and 7 pregnant
patients).
† Excludes all with corticosteroid-induced diabetes mellitus.
‡ Includes 31 patients with not infectious systemic disease, which was also associated with their
uveitis. These patients developed uveitis despite their current immunosuppressive treatment and
uveitis improved in all with an increase of immunosuppressive therapy.
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(n = 2), after organ transplant (n = 1)
and in congenital immunodeﬁciency
syndrome (n = 1). Syphilis was an
important cause of intraocular infec-
tion in HIV-positive population; out of
all 48 HIV-positive patients (indepen-
dently of their CD4 count), 11 (23%)
had uveitis due to syphilis. Out of
these, 6/11 (55%) were not aware of
their positive HIV status, which
became known during the work-up
for their uveitis. Fungal infections did
not occur in HIV, but were observed
in patients on immunosuppressive
medications and in patients with other
causes of immunosuppression (two
posttransplant patients, one with
haematological malignancy during
chemotherapy, one during sepsis after
major surgery, one with congenital
immune deﬁciency syndrome and one
with chronic pancreatitis). Associated
systemic non-infectious diseases were
scarce in immunosuppressed patients
Table 3. Causes of uveitis according to speciﬁc immunocompromised or immunocompetent status of the patients.
Total (N = 1354)
No evidence of
immune suppression
(N = 1075)
Diabetes
mellitus*
(N = 93)
Immune deﬁciency
or suppression,
total† (N = 171)
HIV,
CD4 > 300 cells/mm3
(N = 8)
Pregnancy
(N = 7)
N (%) N (%) N (%) N (%) N (%) N (%)
Infections 220 (16) 125 (12) 8 (9) 78 (46) 7 (87.5) 2 (28)
Viral, total 111 (50) 61 (49) 3 (38) 47 (60) - -
Cytomegalovirus 24 (11) 3 (2.5) - 21 (27) - -
HSV/VZV 45 (21) 23 (18.5) 3 (38) 19 (24) - -
Rubella 30 (14) 28 (22.5) - 2 (2.5) - -
Others 12 (5.5) 7 (5.5) - 5 (6.5) - -
Bacterial, total 43 (20) 18 (1.6) 4 (50) 14 (18) 6 (86) 1 (50)
Treponema
pallidum
12 (5.5) - - 7 (9) -
Others 31 (14) 18 (1.6) 4 (50) 7 (9) 5 (71) 1 (50)
Fungi, total 7 (3) 1 (0.08) - 6 (8) -
Candida 5 (2) - - 5 (6) 1 (14) -
Aspergillus 2 (1) 1 (0.08) - 1 (1) - -
Others - - - - - -
Parasites 58 (26) 45 (4) 1 (13) 11 (14) - 1 (50)
Toxoplasma
gondii
58 (26) 45 (4) 1 (13) 11 (14) - 1 (50)
Not infectious systemic disease 445 (33) 360 (33) 37 (40) 45 (26) 1 (12.5) 2 (28)
Sarcoidosis 185 (42) 148 (41) 21 (57) 16 (36) - -
HLA B27-
associated
83 (19) 74 (20.5) 2 (5.5) 4 (9) 1 (100) 2 (100)
Juvenile
idiopathic
arthritis
48 (11) 44 (12) - 4 (9) - -
Behcet’s disease 28 (6) 25 (7) - 3 (7) - -
VKH disease 17 (4) 17 (5) - - - -
Inﬂammatory
bowel disease
18 (4) 15 (4) 1 (3) 2 (4.5) - -
Granulomatous
polyangiitis
11 (2) 6 (1.6) 3 (8) 2 (4.5) - -
TINU syndrome 7 (1.5) 5 (1.4) - 2 (4.5) - -
Psoriatic
arthritis
8 (2) 4 (1) 1 (3) 3 (7) - -
SLE 4 (0.9) - 1 (3) 3 (7) - -
Others 36 (8) 22 (6) 8 (22) 6 (13) - -
Neurological disease 29 (2) 27 (2.5) 1 (1) 1 (0.5) - -
Ocular clinical syndrome 168 (12) 143 (13) 11 (12) 12 (7) - 2 (28)
Birdshot
chorioretinopathy
61 (36) 57 (40) 3 (27) 1 (8) - -
White dots
syndromes‡
21 (12.5) 19 (13) - - - 2 (100)
Fuchs uveitis syndrome§ 14 (8) 12 (8) 2 (18) - - -
Toxic uveitis 9 (5) 3 (2) 2 (18) 4 (33) - -
Others 63 (37.5) 52 (36) 4 (36) 7 - -
Undetermined 492 (36) 420 (39) 36 (39) 35 (20) - 1 (14)
HIV = human immunodeﬁciency virus, HLA = human leukocyte antigen, HSV = herpes simplex virus, SLE = systemic lupus erythematodes,
TINU = tubulointerstitial nephritis and uveitis, VKH = Vogt-Koyanagi-Harada, VZV = varicella zoster virus.
* Excludes all with corticosteroid-induced diabetes mellitus.
† Includes 31 patients with not infectious systemic disease, which was also associated with their uveitis. These patients developed uveitis despite their
current immunosuppressive treatment and uveitis improved in all with an increase in immunosuppressive therapy.
‡ Other cases than birdshot chorioretinopathy.
§ Includes solely cases with unexplained cause and negative and/or not available intraocular ﬂuid analysis.
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with uveitis, with the exception of 5
biopsy-proven sarcoid reactions in
patients with malignancies (2 with
non-Hodgkin lymphoma, 1 with Hodg-
kin’s disease, 1 with non-seminoma
testis and 1 with combination of rec-
tum and lung carcinoma). Uveitis in
these patients was consistent with the
diagnosis of ocular sarcoidosis and
exhibited mostly features of multifocal
chorioretinitis. The assessment of
intraocular ﬂuid samples in these 5
patients was negative for malignant
cells.
Non-infectious uveitis entities
The prevalence of systemic immune-
mediated diseases did not diﬀer across
the groups with sarcoidosis being the
most prevalent in all groups (immuno-
competent, immunocompromised and
Table 4. Causes of uveitis in immunocompromised patients.
Immune
deﬁciency
or suppression
total
N = 171
HIV+,
CD4 < 300
cells/mm3
N = 40
Immunosuppressive
therapy
(HIV negative)*
N = 52
Malignant disease,
no immunosuppressive
treatment
N = 28
Remaining causes
of immunosuppression
N = 20
Immunosuppresive
therapy for
underlying disease
which caused uveitis
N = 31
N (%) N (%) N (%) N (%) N (%) N (%)
Infections 78 (46) 28 (70) 29 (56) 7 (25) 14 (70) 0
Viral, total 47 (60) 18 (64) 19 (65.5) 6 (86) 4 (18) -
Cytomegalovirus 21 (27) 13 (46) 7 (24) - 1 (4.5) -
HSV/VZV 19 (24) 1 (3.5) 11 (38) 5 (71) 2 (9) -
Rubella 2 (2.5) - - 1 (14) 1 (4.5) -
Others 5 (6.5) 4 (14) 1 (3.5) - - -
Bacterial, total 14 (18) 8 (20) 1 (3.5) - 5 (23) -
Treponema
pallidum
7 (9) 6 (15) - - 1 (4.5) -
Others 7 (9) 2 (7) 1 (3.5) - 4 (18) -
Fungi, total 6 (8) - 3 (10) - 3 (14) -
Candida 5 (6) - 3 (10) - 2 (9) -
Aspergillus 1 (1) - - - 1 (4.5) -
Others - - - - - -
Parasites 11 (14) 2 (7) 6 (21) 1 (14) 2 (9) -
Toxoplasma
gondii
11 (14) 2 (7) 6 (21) 1 (14) 2 (9) -
NISD, total 45 (26) 2 (5) 4 (8) 6 (21) 2 (10) 31
Sarcoidosis 16 (36) 2 (100) 1 (25) 5 (83) - 8 (26)
HLA B27-
associated
4 (9) - 1 (25) 1 (17) - 2 (6)
Juvenile
idiopathic
arthritis
4 (9) - - - - 4 (13)
Behcet’s disease 3 (7) - - - - 3 (10)
VKH disease - - - - - -
Inﬂammatory
bowel disease
2 (4.5) - - - - 2 (6)
Granulomatous
polyangiitis
2 (4.5) - - - - 2 (6)
TINU syndrome 2 (4.5) - - - - 2 (6)
Psoriatic
arthritis
3 (7) - - - - 3 (10)
SLE 3 (7) - - - 1 (50) 2 (6)
Others 6 (13) - 2 (50) - 1 (50) 3 (10)
Neurological disease 1 1
Ocular clinical
syndrome, total
12 (7) 2 (5) 4 (8) 6 (21) - -
Birdshot
chorioretinopathy
1 (8) - - 1 (17) - -
White dots
syndromes*
- - - - -
Fuchs uveitis† - - - 2 (33) - -
Toxic uveitis 4 (33) - 2 (50) 3 (50) - -
Others 7 2 (100) 2 (50) - -
Undetermined 35 (20) 8 (20) 15 (29) 8 4 (20) -
HIV = human immunodeﬁciency virus, HLA = human leukocyte antigen, HSV = herpes simplex virus, SLE = systemic lupus erythematodes,
TINU = tubulointerstitial nephritis and uveitis, VKH = Vogt-Koyanagi-Harada, VZV = varicella zoster virus.
* Other cases than birdshot chorioretinopathy.
† Includes solely cases with unexplained cause and negative and/or not available intraocular ﬂuid analysis.
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DM patients). Established ocular enti-
ties were less prevalent in immunocom-
promised patients 12/171; 7% versus
143/1075; 13%. p = 0.021). The major
causes consisted of birdshot chori-
oretinopathy in immunocompetent
patients and toxic reactions to medica-
tions (cytarabine) in the immunosup-
pressed group.
Discussion
Our study shows a prevalence of 13%of
immunocompromised patients in the
uveitis population from a tertiary refer-
ral centre. We conﬁrm the previously
acknowledged high prevalence of infec-
tious uveitis in immunocompromised
patients (Westeneng et al. 2007) and
make several unknown observations.
First, we show diﬀerent spectrum of
infections in immunocompromised and
immunocompetent patients and further
point out a diﬀerent proﬁle of infections
within the speciﬁc types of immunosup-
pression. HIV-negative patients on
immunosuppressive therapies suﬀered
mostly from infections with HSV/VZV,
whilst HIV–positive patients exhibited
predominantly CMV retinitis and ocu-
lar syphilis. In contrast, patients with
malignancies were characterized by a
lower prevalence of infections and
higher prevalence of sarcoidosis. The
aetiology of uveitis in patients with DM
was similar to immunocompetent
patients, with the exception of higher
prevalence of bacterial intraocular
infections in the DM patients.
So far, the comparison of uveitis
causes for the diﬀerent types of
immunocompromised states was not
performed. Previous reports studied
ocular abnormalities occurring in a
single cause of immunosuppression,
such as after organ and/or hematologic
transplantations or in HIV infections.
The studies of uveitis occurring during
immunosuppressive treatments for
malignant and non-malignant disor-
ders consist of case reports only.
In persons infected with HIV, CMV
retinitis represented the major cause of
ocular morbidity, especially in individ-
uals with low CD4+ T cell counts
(Cunningham & Margolis 1998). The
incidence of CMV retinitis considerably
decreased in countries with available
highly active antiretroviral therapy. In
HIV-infected persons with CD4+ T cell
counts above 200 cells/mm3, infections
still represented a major cause of uveitis
and comprised mainly syphilis and
HSV/VZV infections (Rose-Nussbau-
mer et al. 2014). Further, the prevalence
of immune recovery uveitis (IRU) is
recently rising in this category of
patients (Kempen et al. 2006; Sudhar-
shan et al. 2013). Our data shows that
CMV retinitis occurred in the majority
of our patients with HIV infection
(usually in newly diagnosed patients
with acquired immunodeﬁciency syn-
drome or treatment failures). Our
results also illustrate the rise of ocular
syphilis as an initial indication of HIV
infection, which is obviously not related
to immune deﬁciency, but to the same
route of infection. The exact number of
patientswith IRU inour study couldnot
be determined as the patients were
classiﬁed according to the cause of their
ﬁrst uveitis episode diagnosed in our
department.
The prevalence of speciﬁc causes of
uveitis after the organ and stem cell
transplantations is not known. Several
studies focused on this subject, but due
to scarcity of uveitis after transplanta-
tions (approximately 2%), the number
of aﬀected patients was limited (Ng
et al. 1998; Akova et al. 2006; Akerele
& Lightman 2007; Chung et al. 2007).
The average prevalence ofCMVretinitis
was less than 0.1% in large studies
combining organ and hematologic
transplantations (in contrast to approx-
imately 20–30% in acquired immunod-
eﬁciency syndrome) (Ng et al. 1998;
Akova et al. 2006; Akerele & Lightman
2007; Chung et al. 2007; Tabbara et al.
2009a). Patients with hematologic
malignancies who underwent stem cell
transplantation developed CMV retini-
tis in 0.02–4%; these patients are
severely immunosuppressed and might
represent a diﬀerent category (Crippa
et al. 2001; Tabbara et al. 2009b; Kim
et al. 2016; Yoo et al. 2017). In our
series, themajority of patients after stem
cell transplants suﬀered fromHSV/VZV
infections, which is similar to patients
after organ transplants and those receiv-
ing immunosuppressive treatments for
other causes. However, it should be
taken into account that the number of
patients in speciﬁc immunocompro-
mised groups was limited. Interestingly,
most of the infections in patients under-
going transplantations occurred after
the prophylaxis period, when antibacte-
rial and antiviral drugs were already
stopped. Moreover, transplantation
techniques and prophylactic regimens
develop quickly overtime and recent
reports are associated with declining
numbers of intraocular infections (Stoy-
anova et al. 2014). The infection pre-
vention in other populations
undergoing immunosuppressive treat-
ment is not well deﬁned or not given.
The prevalence of sarcoidosis in our
total series is 14%, which is slightly
higher than approximately 10% in other
European series and could be in part
explained by a sarcoidosis centre located
in our institution (Barisani-Asenbauer
et al. 2012; Jones 2015). However, our
series consist predominantly of patients
referred for their uveitis of yet unknown
cause and possibly the consistent search
for sarcoidosis in our department might
have inﬂuenced the high numbers of
patients diagnosed with sarcoidosis.
High percentage of sarcoidosis in
patients with DM is striking. In patients
with DM, sarcoidosis formed a most
common uveitis cause (23%); the asso-
ciationbetweenDMand sarcoidosiswas
previously noted (Hemminki et al. 2009;
Martusewicz-Boros et al. 2015). Our
study also demonstrates that sarcoid-
reactions in malignancies might include
uveitis (Balasubramaniam et al. 2015).
The anatomical classiﬁcation and
causes of uveitis of our study are roughly
consistent with the previous large series
in uveitis (Barisani-Asenbauer et al.
2012; Bajwa et al. 2015; Jones 2015;
Llorenc et al. 2015; Luca et al. 2017;
Zagora et al. 2017). The number of
patients with anterior uveitis usually
reﬂects the referral pattern in a given
population and is commonly considered
as a measure for severity of uveitis
population (Tomkins-Netzer et al.
2014). The percentage of 35% of ante-
rior uveitis in our series is somewhat
lower than in most tertiary series. Low
prevalence of anterior uveitis in our
centre undoubtedly reﬂects a referral
pattern in the Netherlands and reveals
the severity of our uveitis patients.
Our criteria for the diagnosis of
infectious uveitis were strict and pre-
sumed infections were classiﬁed as of
unknownorigin. Therefore, it is possible
that the prevalence of infections in
immunocompromised patients is even
higher than 43% determined in our
study. Most infections in immunocom-
promised patients progress quickly and
may lead to irreversible blindness. It is
clear that most immunocompromised
patients with infectious uveitis would
beneﬁt from being treated at early stage.
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As the progression can be halted with
antibiotic therapy, the rapid diagnosis
and treatment of immunocompromised
patients is crucial for the visual outcome
andmight prevent permanent visual loss
in these vulnerable patients. Contrary to
the conventional approach, quick
assessment for infections, preferably by
intraocular ﬂuid assessment, should be
performed in all immunocomm-
promised patients with uveitis. In the
Netherlands, national uveitis guidelines
recommend approaching uveitis in
immunocompromised patients as an
emergency and advise to refer patients
on the same day to centres with possi-
bilities of intraocular ﬂuid assessment
and experience in treating such complex
cases. Commonly, the side eﬀects of
multi-medication and resistance to
antibiotics complicate the course of the
ocular disease. The concisemanagement
of immunosuppressed patients with
uveitis may improve their visual out-
comes with relative safety. Due to the
diﬀerent spectrum of uveitis causes, we
believe that the future studies on uveitis
should specify the number of immuno-
suppressed patients included.
In conclusion, our study reveals
diﬀerent spectrum of uveitis in
immunocompetent and immunocom-
promised individuals and demonstrates
that distinct types of immunosuppres-
sion are associated with diﬀerent causes
of uveitis. Speciﬁcally, we show that a
rapid assessment for viral and other
infectious causes should be performed
in all immunosuppressed subjects.
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